Nominations for the 2013 award are now open.
- View the list of all past recipients.
- Learn more about the 2012 recipient, Dr. Jack Cuzick.
The Award and Lecture
The AACR is pleased to sponsor this major international award in recognition of outstanding cancer prevention research. The AACR Award for Outstanding Achievement in Cancer Prevention Research (formerly AACR-Prevent Cancer Foundation Award for Excellence in Cancer Prevention Research) is given to a scientist residing in any country in the world for his or her seminal contributions to the field of cancer prevention. Such investigations must have been conducted in basic, translational, clinical, epidemiological, or behavioral science in cancer prevention research. Further, these studies must have had not only a major impact on the field, but must also have stimulated new directions in this important area.
The recipient of the award will receive a $5,000 honorarium, present a 50-minute lecture at the 12th Annual AACR International Conference on Frontiers in Cancer Prevention Research. The conference will be held October 27-30, 2013, in National Harbor, MD. Support will be given to the recipient and a guest to attend the conference.
Eligibility
- All cancer researchers who are affiliated with any institution involved in cancer research, cancer medicine, or cancer-related biomedical science anywhere in the world are eligible. Such institutions include those in academia, industry, or government.
- The award will be presented to an individual investigator.
- Institutions or organizations are not eligible for the award.
- Candidates must currently maintain an active research program, have a record of recent publications, and be able to present the award lecture at the conference.
Nomination Process
Nominations are now open.
Nominations may be made by any scientist, whether an AACR member or nonmember, who is now or has been affiliated with any institution involved in cancer research, cancer medicine, or cancer-related biomedical science. Candidates may not nominate themselves. There is no restriction on the number of candidates that may be nominated by any individual scientist. There is no restriction on the number of nominators that may write nomination letters or that may sign a single nomination letter on behalf of a candidate.
Nominations must be submitted electronically to
https://proposalcentral.altum.com/, no later than 4 p.m. United States Eastern Time on Thursday, June 20, 2013. Paper nomination will
not be accepted.
The following materials must be submitted:
1) Nomination letter, which must:
- be addressed to the Selection Committee; be written in English; and not exceed 1,000 words;
- specify the AACR award for which the candidate is being nominated;
- describe the candidate's seminal contributions to the field of cancer prevention, with the publications supporting these accomplishments directly referenced within the letter;
- be signed by the nominator(s).
2) Candidate's CV. The candidate's curriculum vitae in English, including a complete list of the candidate's publications.
3) Summary Statement. A statement, no more than 50 words, summarizing the candidate's research accomplishments for which he or she is being nominated.
Your nomination is not considered fully submitted until you receive a confirmation email from the AACR; confirmations will be sent within two business days.
Nominators are asked to maintain the confidentiality of the nomination process and to refrain from informing the candidate about the nomination.
Nomination Instructions
Nominations must be completed online using the proposalCENTRAL website. Full nomination instructions and program guidelines are available through the link below and on the proposalCENTRAL website.
Program Guidelines and Nomination Instructions
Download Adobe Acrobat Reader.
Selection
Candidates will be considered by a committee of international cancer leaders appointed by the president of the AACR. After careful deliberation by the award committee, its recommendations will be forwarded to the executive committee of the AACR for final consideration and decision. Selection of the award winner will be made on the basis of the candidate's seminal contributions to the field of cancer prevention. No regard will be given to age, race, gender, nationality, geographic location, or religious or political views.
Questions?
Linda Stokes, Program Associate
awards@aacr.org
American Association for Cancer Research
17th Floor, 615 Chestnut Street
Philadelphia, PA 19106-4404
(215) 446-7128
SPOTLIGHT
 |
2012 Award Recipient
Jack Cuzick, Ph.D.
John Snow Professor of Epidemiology
Wolfson Institute of Preventive Medicine
Queen Mary University of London
London, England
|
|
Dr. Jack Cuzick is recognized for his outstanding contributions to cancer prevention research in breast, cervical, bowel and prostate cancer.
Dr. Cuzick is trained as a statistician, and was initially involved in trials of cancer treatment. In 1985, Dr. Cuzick made the critical observation that adjuvant tamoxifen reduced the incidence of second primary breast cancers. Dr. Cuzick proposed the use of prophylactic tamoxifen for breast cancer prevention in women at increased risk after providing the scientific basis and justification for the large tamoxifen chemoprevention trials, four of which have now been completed, and all of which have confirmed the results of his original predictions.
Dr. Cuzick was the leader of one of the first definitive trials – the International Breast Cancer Intervention Study (IBIS-I). He built the international infrastructure necessary to carry out this definitive trial, and its successors. The trial also provided data used to develop one of the leading breast cancer risk prediction models available today, and data that uniquely established mammographic density as a modifiable risk biomarker. Dr. Cuzick also published a meta-analysis of the randomized tamoxifen prevention trials which further confirmed that tamoxifen could reduce the incidence of estrogen receptor-positive breast cancer by about 50 percent, and also quantified the adverse effects of the drug.
Dr. Cuzick has also extended his critical work in adjuvant trials of aromatase inhibitors to develop and lead one of the two major trials of aromatase inhibitors for breast cancer prevention (IBIS-II). Further, with Drs. Decensi, Howell and Forbes, Dr. Cuzick has been working to obtain funding for a large international trial, examining the role of metformin, bisphosphonates and extended aromatase inhibitor use in preventing recurrence and new tumors in long-term survivors of large or node positive estrogen receptor-positive breast cancer.
In addition to his truly impressive work in breast cancer prevention, Dr. Cuzick has contributed substantively to screening for cervix, prostate and colorectal cancer. He has led in the establishment of standards for the organization cancer screening programs, has been one of the world’s leading proponents of HPV screening and was a major force in the demonstration of the efficacy of endoscopic screening and its introduction in the UK. Finally, he has created the largest cohort of men with localized prostate cancer managed by watchful waiting from which several useful biomarkers of aggressive disease have emerged. As in all of his efforts, Dr. Cuzick’s vision has permitted the collection of specimens for important biomarker analysis that may help ultimately to focus screening and preventive interventions to individuals at high risk for aggressive disease.
Dr. Cuzick currently serves as head of the Cancer Research UK Centre for Cancer Prevention, is a member of the Cancer Research UK Scientific Advisory Board and president of the International Society for Cancer Prevention.
Dr. Cuzick received his undergraduate degree from Harvey Mudd College, California, and Ph.D. from Claremont Graduate School and worked at Columbia University, New York, and the University of Oxford before moving to London.
Dr Cuzick is the recipient of the Biomedicine Prize for the best paper in a cancer journal (1988), EUROGIN award for distinguished service to cervix cancer (2006), and the Harvey Mudd College Outstanding Alumni Award (2010). He was elected a fellow of the Academy of Medical Sciences (2003) and is an honorary fellow of the Royal College of Physicians (London, 2010).